Abstract: A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises ?? fibrinogen, and wherein concentration or levels of ?? fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Abstract: Recombinant fusion proteins including a dengue virus EIII and an E2 subunit derived from a thermophilic bacterium are described. Also described are expression vectors including a polynucleotide that encodes the recombinant fusion protein and a promoter. Also described are vaccine compositions that include either the recombinant fusion protein, polynucleotide, or both. Also described are methods of generating an immune response to dengue virus serotype 2 comprising administering one or more of the disclosed vaccine compositions.

Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Abstract: A method of making an orthoses, comprising the steps of preparing a plaster mold, upon which the layers of the orthosis will be placed and formed; and placing layers of material on the mold, then forming and removing the layers. An orthosis, comprising a footplate that is capable of receiving a human foot thereabove, a heel portion at the rear side of the footplate; a strut extending upwardly from the heel portion; a calf portion extending forwardly from the strut, the calf portion including a tibial shell; the tibial shell extends around the front of the user's tibia; a rear portion extends around the back of the user's calf a rear portion disposed rearwardly with respect to the calf portion; and sides such that the calf portion is completely circumferential without seams. Two foam layers line the orthoses for comfort and ease of use.